Drugs

Rulemaking History for OTC Exocrine Pancreatic Insufficiency Drug Products

Final Monographs (21 CFR 310.543):
Drug products containing active ingredients offered over-the-counter (OTC) for human use in exocrine pancreatic insufficiency

OTC Exocrine Pancreatic Insufficiency Drug Products found on this page:

Exocrine Pancreatic Insufficiency Drug Products: Original Active Ingredients and Labeling

Advance Notice Of Proposed Rulemaking Date FR Citation
Advance Notice of Proposed Rulemaking 12/21/1979 44FR75666
   Correction 3/25/1980 45FR19266
   Extension of Comment Period 3/25/1980 45FR19265
Proposed Rule Date FR Citation
Tentative Final Monograph Pancreatin and pancrelipase are GRASE 11/8/1985 50FR46594
    Correction 12/2/1985 50FR49409
Proposed Rule: Withdraws tentative final monograph; No GRASE active ingredients 7/15/1991 56FR32282
Notice: Public workshop to discuss testing (needed for NDAs) 3/11/1992 57FR8586
Final Rule Date FR Citation
Final Rule: No GRASE active ingredients 4/24/1995 60FR20162
Notice: Availability of guidance on submitting an NDA 4/28/2004 69FR23414

Exocrine Pancreatic Insufficiency Drug Products: Nonmonograph Ingredients

Proposed Rule Date FR Citation
Proposed Rule: Classifies category II and III ingredients without data as nonmonograph 5/16/1990 55FR20434
   Correction 6/7/1990 55FR23235
Final Rule Date FR Citation
Final Rule: Classifies category II and III ingredients without data as nonmonograph 11/7/1990 55FR46914
   Correction 12/3/1990 55FR49973
   Technical Amendment: Corrects an ingredient name 1/30/1992 57FR3526

Back to Top

Page Last Updated: 06/12/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English